Cilostazol

سیلوستازول

⚠ Unverified

🩸 Blood And Blood Forming OrgansPhosphodiesterase III inhibitor

Market / country: 🇺🇸 USA

Pletal (US)

🧮 Dose calculator

Intermittent claudication (peripheral artery disease) · Regimen source: FDA Cilostazol · 2.1

  • • 30 min before or 2 h after breakfast and dinner. With CYP3A4 or CYP2C19 inhibitors (ketoconazole, erythromycin, diltiazem, omeprazole, fluconazole): 50 mg twice daily. Stop if no improvement after 3 months. FDA Cilostazol · 2.1FDA Cilostazol · 2.2

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Cilostazol · 8.1

    “Teratogenic Effects Pregnancy Category C.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Cilostazol · 8.3

    “Transfer of cilostazol into milk has been reported in rats.”
  • 👶 ChildrenSafety not established

    Label: safety and effectiveness in children have not been established. FDA Cilostazol · 8.4

    “Safety and effectiveness of cilostazol in pediatric patients have not been established.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cilostazol · 8.5

    “… reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be excluded.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

For the same diseases

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Inspired by the Saphira project; part of the content is taken from it.

Contact and correction requests — Telegram: @cenaav